Going back to class I: MHC and immunotherapies for childhood cancer

Pediatric Blood and Cancer

Volumn 62, Issue 4, 2015, Pages 571-576

  Haworth, Kellie B ^a   Leddon, Jennifer L ^a,b,c   Chen, Chun Yu ^a   Horwitz, Edwin M ^a   Mackall, Crystal L ^d   Cripe, Timothy P ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Childhood cancers; Immunotherapy; MHC Class I

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; HISTONE DEACETYLASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VACCINE; HLA ANTIGEN CLASS 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL THERAPY; CHILD; CHILDHOOD CANCER; DOWN REGULATION; EWING SARCOMA; HUMAN; MEDULLOBLASTOMA; NATURAL KILLER CELL; NEUROBLASTOMA; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; ADULT; BIOSYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METABOLISM; NEOPLASMS; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; TRANSPLANTATION;

ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MALE; NEOPLASMS; T-LYMPHOCYTES;

EID: 84923250283     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25359     Document Type: Review

References (43)

1. Ward E, Desantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014: 64:83-103.
2. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, Smith FO, Reaman GH. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol 2010: 28:2625-2634.
3. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 1999:401:921-923.
4. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003: 195:346-355.
5. Licciardi PV, Karagiannis TC. Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol 2012: 2012:690901.
6. Bubenik J. MHC class I down-regulation: Tumour escape from immune surveillance? (review). Int J Oncol 2004: 25:487-491.
7. Bijen CB, Bantema-Joppe EJ, de Jong RA, Leffers N, Mourits MJ, Eggink HF, van der Zee AG, Hollema H, de Bock GH, Nijman HW. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int J Cancer 2010: 126:1417-1427.
8. Hanagiri T, Shigematsu Y, Kuroda K, Baba T, Shiota H, Ichiki Y, Nagata Y, Yasuda M, Uramoto H, So T, Takenoyama M, Tanaka F. Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non-small-cell lung cancer. J Surg Res 2013: 181:e57-e63.
9. Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M, Durrant LG. Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut 2010: 59:926-933.
10. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother 2013: 36:477-489.
11. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pages F. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014: 232:199-209.
12. Inoue M, Mimura K, Izawa S, Shiraishi K, Inoue A, Shiba S, Watanabe M, Maruyama T, Kawaguchi Y, Inoue S, Kawasaki T, Choudhury A, Katoh R, Fujii H, Kiessling R, Kono K. Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology 2012: 1:1104-1110.
13. Maruyama T, Mimura K, Sato E, Watanabe M, Mizukami Y, Kawaguchi Y, Ando T, Kinouchi H, Fujii H, Kono K. Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma. Br J Cancer 2010: 103:552-559.
14. Nasman A, Andersson E, Nordfors C, Grun N, Johansson H, Munck-Wikland E, Massucci G, Dalianis T, Ramqvist T. MHC class I expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome. Int J Cancer 2013: 132:72-81.
15. Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, Ernestus K, Berthold F. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 2005: 54:400-406.
16. Lorenzi S, Forloni M, Cifaldi L, Antonucci C, Citti A, Boldrini R, Pezzullo M, Castellano A, Russo V, van der Bruggen P, Giacomini P, Locatelli F, Fruci D. IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma. PLoS ONE 2012: 7:e46928.
17. Forloni M, Albini S, Limongi MZ, Cifaldi L, Boldrini R, Nicotra MR, Giannini G, Natali PG, Giacomini P, Fruci D. NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells. Cancer Res 2010: 70:916-924.
18. Morandi F, Cangemi G, Barco S, Amoroso L, Giuliano M, Gigliotti AR, Pistoia V, Corrias MV. Plasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patients. Biomed Res Int 2013: 2013:956878.
19. Krishnadas DK, Shapiro T, Lucas K. Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma. Pediatrics 2013: 131:e336-e341.
20. Berghuis D, de Hooge AS, Santos SJ, Horst D, Wiertz EJ, van Eggermond MC, van den Elsen PJ, Taminiau AH, Ottaviano L, Schaefer KL, Dirksen U, Hooijberg E, Mulder A, Melief CJ, Egeler RM, Schilham MW, Jordanova ES, Hogendoorn PC, Lankester AC. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: Implications for immune recognition. The Journal of pathology 2009: 218:222-231.
21. Borowski A, van Valen F, Ulbrecht M, Weiss EH, Blasczyk R, Jurgens H, Gobel U, Schneider EM. Monomorphic HLA class I-(non-A, non-B) expression on Ewing's tumor cell lines, modulation by TNF-alpha and IFN-gamma. Immunobiology 1999: 200:1-20.
22. Peters HL, Yan Y, Solheim JC. APLP2 regulates the expression of MHC class I molecules on irradiated Ewing's sarcoma cells. Oncoimmunology 2013: 2:e26293.
23. Smith C, Santi M, Rajan B, Rushing EJ, Choi MR, Rood BR, Cornelison R, MacDonald TJ, Vukmanovic S. A novel role of HLA class I in the pathology of medulloblastoma. J Transl Med 2009: 7:59.
24. Fernandez L, Portugal R, Valentin J, Martin R, Maxwell H, Gonzalez-Vicent M, Diaz MA, de Prada I, Perez-Martinez A. In vitro natural killer cell immunotherapy for medulloblastoma. Front Oncol 2013: 3:94.
25. Mechtersheimer G, Staudter M, Majdic O, Dorken B, Moldenhauer G, Moller P. Expression of HLA-A, B, C, beta 2-microglobulin (beta 2m), HLA-DR, -DP, -DQ and of HLA-D-associated invariant chain (Ii) in soft-tissue tumors. Int J Cancer 1990: 46:813-823.
26. Motawi TM, Zakhary NI, Salman TM, Tadros SA. Serum human leukocyte antigen-G and soluble interleukin 2 receptor levels in acute lymphoblastic leukemic pediatric patients. Asian Pac J Cancer Prev 2012: 13:5399-5403.
27. Reid GS, Terrett L, Alessandri AJ, Grubb S, Stork L, Seibel N, Gaynon P, Schultz KR. Altered patterns of T cell cytokine production induced by relapsed pre-B ALL cells. Leuk Res 2003: 27:1135-1142.
28. Orentas RJ, Lee DW, Mackall C. Immunotherapy targets in pediatric cancer. Front Oncol 2012: 2:3.
29. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003: 26:332-342.
30. Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, van Rooij N, Linnemann C, van Buuren MM, Urbanus JH, Beltman JB, Thor Straten P, Li YF, Robbins PF, Besser MJ, Schachter J, Kenter GG, Dudley ME, Rosenberg SA, Haanen JB, Hadrup SR, Schumacher TN. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 2012: 1:409-418.
31. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013: 39:38-48.
32. Krishnadas D, et al. Cancer Testis Antigen and Immunotherapy. Immunotargets and Therapy 2013: 2:11-19.
33. Miest TS, Cattaneo R. New viruses for cancer therapy: Meeting clinical needs. Nat Rev Microbiol 2014: 12:23-34.
34. Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: Sharpening the sword for improved cancer treatment strategies. Mol Ther 2014: 22:251-256.
35. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit AT melanoma patients. Clin Cancer Res 2013: 19:5300-5309.
36. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, Keiser N, Santaniello F, Tomasi TB. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 2000: 165:7017-7024.
37. Long EO. Negative signaling by inhibitory receptors: The NK cell paradigm. Immunol Rev 2008: 224:70-84.
38. Palmer JM, Rajasekaran K, Thakar MS, Malarkannan S. Clinical relevance of natural killer cells following hematopoietic stem cell transplantation. J Cancer 2013: 4:25-35.
39. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013: 31:227-258.
40. Chouaib S, Pittari G, Nanbakhsh A, El Ayoubi H, Amsellem S, Bourhis JH, Spanholtz J. Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies. Front Immunol 2014: 5:95.
41. Locatelli F, Pende D, Maccario R, Mingari MC, Moretta A, Moretta L. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: How NK cells make the difference. Clin Immunol 2009: 133:171-178.
42. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007: 109:5058-5061.
43. Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu J. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014: 28:917-927.